SecBot SecBot
8-K ·Filed May 18, 2026

NBIX

NEUROCRINE BIOSCIENCES INC
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001193125-26-228013
8-K material event: Items 1.01, 2.01
Actionable Insight ▲ Bullish

The deal closure removes overhang uncertainty and adds a recently approved, first-in-class commercial asset (VYKAT XR) with strong early adoption potential. The $600M initial draw on the new credit facility increases leverage but is manageable given Neurocrine's cash flow profile (INGREZZA). Focus on VYKAT XR revenue trajectory and integration execution are the key near-term catalysts. Monitor next quarterly report for initial VYKAT XR sales and updated 2026 guidance reflecting the acquisition.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$156.73
T+0 close · May 18, 2026 · via day close
Latest settled
−0.15%
T+60 · $156.49
Vs SPY
−4.73%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $156.73entry
  2. T+1 · 6mo ago −1.81%α −1.16% · $153.90
  3. T+5 · 6mo ago −0.64%α −2.26% · $155.72
  4. T+20 · 5mo ago +1.78%α −0.41% · $159.51
  5. T+60 · 3mo ago −0.15%α −4.73% · $156.49

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Neurocrine Biosciences closed its $2.9B acquisition of Soleno Therapeutics on May 18, 2026, adding VYKAT XR (diazoxide choline) for hyperphagia in Prader-Willi syndrome to its rare disease portfolio. Concurrently, Neurocrine entered into a $1.0B senior secured revolving credit facility and borrowed $600M on the closing date to fund the acquisition and for general corporate purposes. The combination of the closed transformative acquisition and the new debt facility represents a significant strategic deployment of capital.

Key Financial Metrics

Deal Value
$2.9B
Deal Type
merger

Key Facts

  • Acquisition of Soleno Therapeutics closed on May 18, 2026, for total equity value of $2.9B ($53.00 per share in cash).
  • 88.9% of Soleno shares (46,356,114 shares) validly tendered in the offer; remaining shares converted at same $53.00 per share in the merger.
  • Addition of VYKAT XR, the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, a ~10,000-patient U.S. market.
  • New $1.0B five-year senior secured revolving credit facility entered into on May 14, 2026, with an initial $600M draw.
  • Total Net Leverage Ratio covenant of 3.75:1.00 (4.25:1.00 after qualifying acquisitions); minimum Interest Coverage Ratio of 2.00:1.00.
  • Prior analysis on the April 6 deal announcement was bullish with an impact score of 8/10.

Financial Impact

Total equity value of $2.9 billion paid in cash, funded from available cash on hand. New $1.0 billion revolving credit facility established with $600 million drawn on closing.

debtdilutionrevenuecash

Risk Factors

  • Integration risk of Soleno operations and commercial launch.
  • VYKAT XR market uptake may be slower than expected in the PWS indication.
  • Increased leverage from the $600M draw and potential future draws; covenants tested quarterly.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-228013
Document: d94926d8k.htm0001193125-26-228013
Document: d94926dex991.htm0001193125-26-228013
Document: 0001193125-26-228013-index-headers.html0001193125-26-228013
Document: 0001193125-26-228013-index.html0001193125-26-228013
Document: 0001193125-26-228013.txt0001193125-26-228013

Track record

30 reports on NBIX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
  2. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  3. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  4. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  5. Nov 2, 202614d ago Press Release Bullish 6/10 No price data
  6. Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
  7. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
  8. Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
  9. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
  10. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
Showing 10 of 30

US Market Status

Market Closed · Opens in 7h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026